Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

le metabolic effects in healthy subjects, together with the safety profile observed to date, suggest that LX4211 could be considered earlier in the diabetes treatment paradigm, perhaps including the potential treatment of pre-diabetes in patients with impaired glucose tolerance or impaired fasting glucose (IGT/IFG)."

About the Clinical Trial

The clinical trial was designed to assess the effect of different LX4211 dose schedules relative to meal time  in healthy subjects when taken as a single daily dose (400 mg) or a split dose (200 mg twice daily).  Subjects were randomized to LX4211 in an ordered sequence to assess the pharmacodynamic effects of different dosing times, ranging from 1 hour prior to meals to immediately prior to meals.  Pharmacodynamic effects, include urinary glucose excretion, fasting plasma glucose, insulin, PYY and GLP-1 (total and active) were assessed at multiple time points during the 12-day dosing period.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing o
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific has ... Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, ... investigating vagus nerve stimulation (VNS) for the treatment ... Professor of Therapeutics and Cardiology and Director of ... de la Sante et de la Recherche Medicale ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... Jan. 25, 2012  Amorcyte, LLC, a NeoStem, Inc. ... announces the enrollment of the first patient in ... myocardial infarction. The study is a multicenter, randomized, ... and efficacy of infarct-related artery infusion of AMR-001, ...
... hosting a free webinar on the upcoming changes to the ... and is intended to address the growing number of questions ... (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ) "We,ll do ... the current status and upcoming changes, as well as insight ...
Cached Medicine Technology:Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
(Date:8/30/2014)... Zensah®, the leader in compression technology and ... as a best-seller within golf and tennis. Golfers and tennis ... enjoy most by using the compression elbow sleeve to help ... a condition that causes pain on the inner side of ... to the bony bump on the inside of your elbow. ...
(Date:8/30/2014)... 31, 2014 Atlanta based automotive group ... help raise money and awareness for ALS by participating ... Managers, staff, and even Vice President Jimmy Ellis all ... and can be viewed on their Youtube page; ... challenge, general managers and staff also took the opportunity ...
(Date:8/30/2014)... Recently, Top 10 Best SEO Hosting ... announced that BlueHost and JustHost ( http://www.justhost.com/track/seohosts ) ... to buy high quality web hosting. , ... web host companies who outperform their competitors on ... support.” A spokesman for Top 10 Best SEO ...
(Date:8/30/2014)... UWDress.com, a distinguished wedding dress supplier, has gained ... of fashionable outfits. Recently, the company has unveiled its beautiful ... autumn special offer, all these brand new products are provided ... “We are excited to unveil the new and trendy bridesmaid ... products are available at low prices now. The purpose of ...
(Date:8/30/2014)... (PRWEB) August 31, 2014 Recently, iFitDress.com, ... announced its new designs of classy bridesmaid dresses ... big discounts (from 22 percent off to 62 percent ... these extremely beautiful items. , True enough, iFitDress.com ... women’s special occasion gowns. The company persists in making ...
Breaking Medicine News(10 mins):Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Great Web Hosting Suppliers Recently Recommended by Top10BestSEOHosting.com 2Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2Health News:Classy Bridesmaid Dresses Announced By Loved Online Supplier iFitDress.com 2
... (Pink Sheets: BPYT) ("Bioponic"), an innovative provider of ... (CAM) and nutraceutical markets, announced today that it ... Financial,Communications Corporation, as its investor relations representative. ... and approximately 62% of U.S.,adults are using some ...
... disease, study finds , , THURSDAY, Oct. 4 (HealthDay News) -- ... the heart,s left main artery should take special care of ... sisters of someone with such problems are 2.5 times more ... the siblings of patients with heart disease not related to ...
... ROCKVILLE, Md., Oct. 4 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases,announced today ... Officer,will present a Company overview at the Biotechnology ... Palace Hotel, San Francisco,California, October 9-11, 2007. Mr. ...
... Oct. 4 According to the,November 2006 Rand ... alone costs about $6.4 billion a year nationally ... If another amnesty were adopted,tens of millions of ... be added within 20 years to the U.S. ...
... The National Confectioner,s,Association has noted that up to ... this in mind, Halloween is a perfect time ... children. "Since candy and Halloween go together...Consider ... can enjoy chocolate and,lollipops on occasion as long ...
... following is a,statement by Michael Bender, director of The ... Food and Drug Administration and its various,expert groups, and ... years to present a balanced and clear message in ... there is,there is enough mercury in certain fish to ...
Cached Medicine News:Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 3Health News:Cardiac Artery Trouble Boosts Family Heart Risk 2Health News:Cardiac Artery Trouble Boosts Family Heart Risk 3Health News:EntreMed to Present at the Bio 2007 Investor Forum 2Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Parents can Help Young Superheroes Battle Cavities on Halloween Night 2Health News:New Fish Advice Throws Baby Out With the Bath Water, Says Mercury Watchdog Group 2
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
... the need for makeshift, modified nebulizer setups ... time gathering parts when your patient is ... deliver the utmost in Heliox rescue therapy. ... fast becoming the standard of care in ...
Medicine Products: